Navidea Biopharmaceuticals (NAVB +1.9%) gains after Burrill Institutional Research initiated the...
Tuesday, January 22, 12:32 PM ETNavidea Biopharmaceuticals (NAVB +1.9%) gains after Burrill Institutional Research initiated the shares with a Market Outperform on valuation and a price target of $5 a share. The firm says the stock represents an undervalued opportunity with multiple near-term drivers that are likely to create shareholder value in 2013. Separately, Aegis Capital starts the stock with a Hold rating and a $3.00 price target.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles